The UK BioIndustry Association (BIA) published their report "Celebrating UK Bioscience: unravelling the stories behind UK bioscience success" at their annual Parliament Day hosted on 25 June at the Houses of Parliament. In this report UK Business leaders are calling for a policy and funding environment that continues to support world-leading universities, as their contribution is crucial to a thriving commercial bioscience sector.

One of the case studies of bioscience success included Lemtrada (alemtuzumab), previously known as CAMPATH. The Clinical BioManufacturing Facility (then known as the Therapeutic Antibody Centre, TAC) at the University of Oxford was built in order to translate the academic research of therapeutic monoclonal antibody pioneers Profs Herman Waldmann and Geoff Hale (see also CBF History). The TAC opened in Oxford in 1995 for manufacture of CAMPATH and other monoclonal antibodies, which spent much of their clinical development in Oxford.

The Clinical BioManufacturing Facility (CBF) is now part of the Nuffield Department of Medicine's Jenner Institute and is involved in early development of novel vaccines and gene therapy products, helping academic researchers make rapid progress into Phase I/II trials. For the transition from manufacturing monoclonal antibodies to viral vectored vaccines and gene therapies the CBF and Jenner researches worked closely with the MHRA (see recent MHRA innovation office article).

Since 2007, the CBF manufactured 17 batches of vaccines and ATMPs which were used in over 25 first in human phase I/II clinical trials  (covering malaria, TB, flu, HIV, HCV, prostate cancer), with several products and trials in the pipeline. The CBF also imports and certifies investigational medicinal products from other manufacturers for use in clinical trials in a wide range of disease areas, including Ebola and choroideremia, a genetic condition that leads to blindness.

 

MS for lemtrada